Your browser doesn't support javascript.
loading
Differential Synaptic Loss in ß-Amyloid Positive Versus ß-Amyloid Negative Corticobasal Syndrome.
Holland, Negin; Savulich, George; Jones, P Simon; Whiteside, David J; Street, Duncan; Swann, Peter; Naessens, Michelle; Malpetti, Maura; Hong, Young T; Fryer, Tim D; Rittman, Timothy; Mulroy, Eoin; Aigbirhio, Franklin I; Bhatia, Kailash P; O'Brien, John T; Rowe, James B.
  • Holland N; Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Savulich G; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
  • Jones PS; Department of Psychiatry, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Whiteside DJ; Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Street D; Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Swann P; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
  • Naessens M; Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Malpetti M; Department of Psychiatry, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Hong YT; Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Fryer TD; Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Rittman T; Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Mulroy E; Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, United Kingdom.
  • Aigbirhio FI; Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Bhatia KP; Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, United Kingdom.
  • O'Brien JT; Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Rowe JB; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
Mov Disord ; 39(7): 1166-1178, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38671545
ABSTRACT
BACKGROUND/

OBJECTIVE:

The corticobasal syndrome (CBS) is a complex asymmetric movement disorder, with cognitive impairment. Although commonly associated with the primary 4-repeat-tauopathy of corticobasal degeneration, clinicopathological correlation is poor, and a significant proportion is due to Alzheimer's disease (AD). Synaptic loss is a pathological feature of many clinical and preclinical tauopathies. We therefore measured the degree of synaptic loss in patients with CBS and tested whether synaptic loss differed according to ß-amyloid status.

METHODS:

Twenty-five people with CBS, and 32 age-/sex-/education-matched healthy controls participated. Regional synaptic density was estimated by [11C]UCB-J non-displaceable binding potential (BPND), AD-tau pathology by [18F]AV-1451 BPND, and gray matter volume by T1-weighted magnetic resonance imaging. Participants with CBS had ß-amyloid imaging with 11C-labeled Pittsburgh Compound-B ([11C]PiB) positron emission tomography. Symptom severity was assessed with the progressive supranuclear palsy-rating-scale, the cortical basal ganglia functional scale, and the revised Addenbrooke's Cognitive Examination. Regional differences in BPND and gray matter volume between groups were assessed by ANOVA.

RESULTS:

Compared to controls, patients with CBS had higher [18F]AV-1451 uptake, gray matter volume loss, and reduced synaptic density. Synaptic loss was more severe and widespread in the ß-amyloid negative group. Asymmetry of synaptic loss was in line with the clinically most affected side.

DISCUSSION:

Distinct patterns of [11C]UCB-J and [18F]AV-1451 binding and gray matter volume loss, indicate differences in the pathogenic mechanisms of CBS according to whether it is associated with the presence of Alzheimer's disease or not. This highlights the potential for different therapeutic strategies in CBSs. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sinapsis / Péptidos beta-Amiloides / Tomografía de Emisión de Positrones Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sinapsis / Péptidos beta-Amiloides / Tomografía de Emisión de Positrones Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2024 Tipo del documento: Article